AKT1 and esophageal squamous cell carcinoma: Three small molecule inhibitors were therefore selected for testing in ESCC cells in the first instance, targeting AKT [MK-2206 and capivasertib (AZD5363)] or mTORC1/2 (PP242) (Figure S8A).